Abstract: Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

Abstract: A compound of formula (1) R1—Wm—Xn-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp—Zq—R2, wherein AA1 is Phe; AA2 is Trp; AA3 is selected from Met, Leu and lie; AA4 is selected from Lys, Arg and Gln; AA5 is Arg; AA6 is Lys; AA7 is selected from Arg, Lys and His; AA8 is selected from Val, Ile, Leu and Met; and AA9 is Pro. The compound is useful in the treatment and/or care of the skin, hair, nails and/or mucous membranes, in particular for improving the barrier function of the skin, for energizing the skin and as an anti-aging agent.

Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.

Abstract: The present invention provides compounds of formula (I) wherein X1, X2, R1 to R6 and A are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by bacteria.

Abstract: Modified hum1.an factor VIII polypeptides with enhanced factor VIII activity are described. In some embodiments, the modified human factor VIII polypeptides comprise one or more amino acid substitutions at positions A20, T21, P57, L69, I80, L178, R199, H212, I215, R269, I310, L318, S332, R378, I610 and/or I661. Such polypeptides and viral vectors encoding such polypeptides may be used for treatment of FVIII deficiencies, such as hemophilia A.

Abstract: The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.

Abstract: Compositions comprising synergistic blends of organic acids and hydrazones and methods of reducing bacterial and fungal contamination using the blends are disclosed.

Abstract: Provided are a multilayer film having excellent gas permeability and excellent handling properties and hence is suited for forming a cell culture container, and a cell culture container formed by using the same. A multilayer film used for forming a cell culture container, comprising: a base material composed of a polyethylene-based resin having a density of 0.87 g/cm3 to 0.90 g/cm3; and an inner layer composed of a polyethylene-based resin having a density of 0.896 g/cm3 to 0.93 g/cm3 and forming a cell culture icy surface. A cell culture container is formed by using this multilayer film.

Abstract: This disclosure provides a method for determining male fertility status. The method comprises determining GM1 distribution patterns following induced sperm capacitation, identifying the frequency of distribution of various patterns, and determining if the frequency distribution of certain GM1 patterns in response to induced capacitation is altered. Based on the change in the frequency distribution patterns of certain patterns in response to induced capacitation, alone or in combination with other sperm attributes, male fertility status can be identified.

Abstract: Described herein are an aspirin or active aspirin derivative and a COX-2 inhibitor, at least one of which has an enteric or partial enteric coating, administered in combination yet delivered sequentially, for the treatment and prophylactic treatment of diseases, symptoms and conditions. In some embodiments, the COX-2 inhibitor has the enteric coating; however, the aspirin or active aspirin derivative may additionally or alternately have the enteric coating. In all embodiments, the drug having the enteric coating or enteric formulation is targeted for absorption in the small intestine or colon, or both the small intestine and the colon.

Abstract: Embodiments of the invention relate generally to protein extraction and, more generally, to bone protein extraction methods that do not require demineralization. In one embodiment, the invention provides a method comprising: mixing a bone sample and a quantity of an extraction buffer comprising: ammonium phosphate dibasic; or ammonium phosphate dibasic and ammonium bicarbonate; or ammonium phosphate dibasic, ammonium bicarbonate, and guanidine HCl; or sodium phosphate dibasic and sodium bicarbonate; or sodium phosphate dibasic, sodium bicarbonate, and guanidine HCl; or potassium phosphate dibasic and potassium bicarbonate; or potassium phosphate dibasic, potassium bicarbonate, and guanidine HCl; and incubating the bone sample/extraction buffer mixture.

Abstract: Compositions, articles, and methods for targeted drug delivery, such as thermoresponsive hydrogel polymers, are generally provided. In one aspect, the compositions and articles comprise a thermoresponsive hydrogel polymer comprising a releasable therapeutic agent. In some cases, the compositions described herein have advantageous combinations of properties including mechanical strength, biocompatibility, tunable charge densities, thermal responsiveness, drug loading, and/or configurations for targeted drug delivery. In one embodiment, the composition comprises a solution comprising a thermoresponsive polymer including one or more ligands attached to the polymer, wherein the solution is configured to undergo a sol-to-gel transition under physiological conditions. In another embodiment, the composition comprises a plurality of nanoparticles e.g., associated with the thermoresponsive polymer. In yet another embodiment, the composition comprises a therapeutic agent e.g.

Abstract: The invention provides a method for producing methacrylyl-CoA that converts 3-hydroxyisobutyryl-CoA into methacrylyl-CoA using an enzyme having dehydratase activity as a method for producing methacrylyl-CoA using an enzyme catalyst. In this production method, conversion rate of 3-hydroxyisobutyryl-CoA into methacrylyl-CoA by the enzyme having dehydratase activity is 50% or higher. In this production method, furthermore, the enzyme having dehydratase activity derives from a microorganism belonging to the genus Pseudomonas or Rhodococcus.

Abstract: Pressed powder compositions are provided. The compositions include at least about 80% by weight of a mineral portion. The mineral portion comprises at least one alkylsilane-coated mineral; polyhydroxystearic acid, synthetic mica, and less than about 12% by weight of binding agents. Methods of shadowing the eyes and methods of forming pressed powder compositions are also provided.

Abstract: Provided is a white pigment for cosmetics capable of giving a cosmetic that gives a coating film having less stickiness and higher long-lasting properties. A white pigment for cosmetics of the present invention includes a titanium phosphate powder, the titanium phosphate powder includes crystal particles of titanium phosphate, and a ratio (oil absorption value/specific surface area) of an oil absorption value (ml/100 g) to a specific surface area (m2/g) of the crystal particles is 2.0 or more.

Abstract: The present invention includes a method and apparatus for measuring the transport of analytes from living, biological cells through a cell barrier, which includes, but is not limited to, steps of providing the living, biological cells loaded with analytes, unloading at least a portion of said analytes from the cells through ion channels, removing unloaded analyte remaining in the cells, and measuring the analytes using x-ray fluorescence, specifically wherein the measurement uses an energy dispersive x-ray fluorescence spectrometer equipped with a microfocus x-ray tube. These steps may be repeated so that multiple measurements can be obtained over a period of time.

Abstract: A topical sanitizing composition for reducing the concentration of non-enveloped viruses on the skin is provided. The topical sanitizing composition includes one or more pH adjusters, at least one carbomer, and at least about 50 wt. % of one or more C1-8 alcohols. The sanitizing composition with pH adjuster and carbomer is able to achieve at least a 3.0 log reduction in the concentration of the non-enveloped virus and in some cases passes the EN 14476 standard.

Abstract: A biochemical scaffold for regulating mammalian cell function. The biochemical scaffold includes a base liquid medium, a bioenergetic platform and a vibrational platform. The bioenergetic platform includes at least one Krebs cycle modulator and the vibrational platform includes at least one energy signature component, e.g., an herb. The biochemical scaffold is subjected to sequential harmonic oscillation at defined frequency ranges for a defined, predetermined period of time, wherein the energy signature of the energy signature component is imparted to, captured, replicated, and retained by liquid medium, and, when the biochemical scaffold is delivered to and, thus, in communication with biological tissue, the biochemical scaffold induces specific biochemical activities via the resonant transfer of the retained energy signature to the biological tissue and, hence, endogenous cells thereof, the biochemical activities including increased bioavailability of ATP.

Abstract: An anhydrous alcohol gel formulation. The gel formulation comprises one or more film forming agents, one of which is TM-Si 5. The gel formulation comprises active agent(s), which differs based on the purpose of the gel formulation. In certain embodiments, the gel formulation comprises one or more emollients. In certain embodiments, the gel formulation comprises one or more viscosity increasing agents. In certain embodiments, the gel formulation comprises Zinc Oxide. The formulation optionally comprises other ingredients. Such optional ingredients include: a skin conditioning and/or bulking agent; a fragrance, such as, for example and without limitation, Fragrance SZ-2108 MOD 2010; etc.

Abstract: Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores ranging from 50 ? to 40,000 ? with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and sorbing the toxin. Also provided are kits to reduce contamination by one or more toxins in a biological substance comprising a sorbent capable of sorbing a toxin, wherein the sorbent comprises a plurality of pores ranging from 50 ? to 40,000 ? with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and a vessel to store said sorbent when not in use together with packaging for same.